Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Pre-Mkt 10-19 07:41:05 EDT

33.53

-0.51

-1.50%

盘前33.78

+0.25+0.75%

07:21 EDT

High34.12	Low33.23	Vol4.92M
Open34.12	D1 Closing34.04	Amplitude2.61%
Mkt Cap24.22B	Tradable Cap19.48B	Total Shares722.41M
T/O164.99M	T/O Rate0.85%	Tradable Shares581.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":33.53,"timestamp":1792180800000,"preClose":34.04,"halted":0,"volume":4923609,"hourTrading":{"tag":"盘前","latestPrice":33.78,"preClose":33.53,"latestTime":"07:21 EDT","volume":1647,"amount":55875.968829000005,"timestamp":1792408883078,"change":0.25,"changeRate":0.007456,"amplitude":0.025947},"delay":0,"changeRate":-0.014982373678025794,"floatShares":581000000,"shares":722406273,"eps":-0.47,"marketStatus":"Pre-Mkt","change":-0.51,"latestTime":"10-19 07:41:05 EDT","open":34.12,"high":34.12,"low":33.23,"amount":164985066.27273,"amplitude":0.026146,"askPrice":33.77,"askSize":59,"bidPrice":33.54,"bidSize":59,"shortable":3,"etf":0,"ttmEps":-0.47,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1792416600000},"marketStatusCode":1,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":33.53,"preHourTrading":{"tag":"盘前","latestPrice":33.78,"preClose":33.53,"latestTime":"07:21 EDT","volume":1647,"amount":55875.968829000005,"timestamp":1792408883078,"change":0.25,"changeRate":0.007456,"amplitude":0.025947},"postHourTrading":{"tag":"盘后","latestPrice":33.53,"preClose":33.53,"latestTime":"19:30 EDT","volume":335400,"amount":11245949.1971,"timestamp":1792193405389,"change":0,"changeRate":0,"amplitude":0.002386},"volumeRatio":0.967320136377109,"impliedVol":0.4369,"impliedVolPercentile":0.668},"requestUrl":"/m/hq/s/ROIV","defaultTab":"news","newsList":[{"id":"2675383137","title":"Citi opens ‘upside 90-day catalyst watch’ on Roivant Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2675383137","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675383137?lang=en_us&edition=fundamental","pubTime":"2026-10-13 06:50","pubTimestamp":1791845411,"startTime":"0","endTime":"0","summary":"Citi analyst Samantha Semenkow added an “upside 90-day catalyst watch” on Roivant Sciences (ROIV) while keeping a Buy rating on the shares with a $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citi-opens-upside-90-day-catalyst-watch-on-roivant-sciences-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citi-opens-upside-90-day-catalyst-watch-on-roivant-sciences-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTH","ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675838842","title":"Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Bristol-Myers Squibb (BMY) and Palvella Therapeutics (PVLA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2675838842","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675838842?lang=en_us&edition=fundamental","pubTime":"2026-10-13 06:00","pubTimestamp":1791842428,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roivant Sciences (ROIV), Bristol-Myers Squibb (BMY...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-roivant-sciences-roiv-bristol-myers-squibb-bmy-and-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-roivant-sciences-roiv-bristol-myers-squibb-bmy-and-palvella-therapeutics-pvla-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0882574055.USD","LU1074936037.SGD","LU1236620834.HKD","LU0306807586.USD","ROIV","IHE","LU1983299246.USD","LU1571399168.USD","LU1883839398.USD","LU1670711040.USD","LU0321505868.SGD","HCSG","BK4588","BK4534","LU1585245621.USD","LU2242646821.SGD","BK4559","LU0432979614.USD","LU1236620750.USD","LU0985481810.HKD","LU1291159041.SGD","FTXH","LU1430594728.SGD","LU1718418525.SGD","IE00BSNM7G36.USD","XLV","BK4585","LU0096364046.USD","LU1261432733.SGD","LU1093756168.USD","BMY","LU2133065610.SGD","LU0456855351.SGD","LU0225284248.USD","XBI","PVLA","LU1670710661.SGD","LU1868836591.USD","LU2125154778.USD","LU2125154935.USD","BK4007","LABU","PTH","LU1323610961.USD","BK4532","BK4137","LU1868837300.USD","LU0237698245.USD","LU0306806265.USD","IE00BFXG1179.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674088878","title":"Analysts Conflicted on These Healthcare Names: ProKidney (PROK) and Roivant Sciences (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674088878","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674088878?lang=en_us&edition=fundamental","pubTime":"2026-10-12 20:50","pubTimestamp":1791809416,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on ProKidney (PROK) and Roivant Sciences (ROIV). ProKidney (PROK) Ba...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-prokidney-prok-and-roivant-sciences-roiv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-prokidney-prok-and-roivant-sciences-roiv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","XLV","BK4581","BK4585","LU0128526141.USD","ROIV","BK4588","PROK","BK4137","HCSG","PTH","BK4139","LU0029874061.USD","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674770268","title":"Roivant Sciences Cut to Peer Perform from Outperform by Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2674770268","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674770268?lang=en_us&edition=fundamental","pubTime":"2026-10-12 20:20","pubTimestamp":1791807600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTH","BK4007","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673062023","title":"How $950 Million Settlement Will Impact Roivant Sciences Stock (ROIV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2673062023","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673062023?lang=en_us&edition=fundamental","pubTime":"2026-10-07 09:22","pubTimestamp":1791336149,"startTime":"0","endTime":"0","summary":"Roivant Sciences reported a quiet Q1 2026 but highlighted progress across its inflammation and immunology pipeline, alongside a US$950 million settlement received from Moderna related to lipid nanoparticle litigation.\nThe combination of a large cash infusion from the settlement and advancing brepocitinib programs gives Roivant Sciences added financial and operational flexibility as it manages ongoing R&D and continuing legal action against Pfizer and BioNTech.\nWe will now examine how Roivant...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/how-950-million-settlement-will-impact-roivant-sciences-stoc","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/how-950-million-settlement-will-impact-roivant-sciences-stoc","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4007","ROIV","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673087032","title":"Immunovant CEO Eric Venker Disposes of Common Shares Worth $2.93 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2673087032","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673087032?lang=en_us&edition=fundamental","pubTime":"2026-10-06 07:43","pubTimestamp":1791243789,"startTime":"0","endTime":"0","summary":"Immunovant CEO Eric Venker disposes of common shares worth $2.93 millionImmunovant CEO and director Eric Venker increased his direct stake to 257,075 shares following CVAR settlement.92,187 shares wer","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261005:nNDL8Rvzcp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4139","ROIV","BK4007","IMVT","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672419217","title":"Roivant President and Immunovant CEO Eric Venker Disposes of 200,000 Common Shares Worth $7,324,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2672419217","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672419217?lang=en_us&edition=fundamental","pubTime":"2026-10-03 05:38","pubTimestamp":1790977094,"startTime":"0","endTime":"0","summary":"Roivant President and Immunovant CEO Eric Venker disposes of 200,000 common shares worth $7,324,000Roivant Sciences President and Immunovant CEO Eric Venker sold 200,000 common shares at a weighted-av","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261002:nNDL6N8y8r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","IMVT","BK4139","BK4007","BK4588","PTH","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672751724","title":"Arbutus Biopharma Buys Back 46,000,000 Shares for US$ 230 Million in Dutch Auction Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2672751724","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672751724?lang=en_us&edition=fundamental","pubTime":"2026-10-01 19:32","pubTimestamp":1790854322,"startTime":"0","endTime":"0","summary":"Arbutus Biopharma buys back 46,000,000 shares for US$ 230 million in Dutch auction tender offerArbutus completed a modified Dutch auction tender offer, repurchasing 46,000,000 common shares for cancel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL6Zy8XC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","BK4112","SG9999014005.SGD","IE00BN0W2T93.GBP","ABUS","BCDF","PTH","BK4007","LU2210150020.SGD","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK4585","IE00BN0W2W23.USD","IE00B3QW5Z07.USD","SG9999014039.USD","IE00BQXX3C00.GBP","SG9999014021.USD","BK4139","BK4588","IE00BQXX3F31.USD","LU0314104364.USD","ROIV","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","NDAQ","IE00BKPKM429.USD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671093162","title":"Arbutus Biopharma Repurchases 46,000,000 Shares for USD 230 Million in Modified Dutch Auction Tender Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2671093162","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671093162?lang=en_us&edition=fundamental","pubTime":"2026-09-30 19:30","pubTimestamp":1790767828,"startTime":"0","endTime":"0","summary":"Arbutus Biopharma repurchases 46,000,000 shares for USD 230 million in modified Dutch auction tender offerArbutus Biopharma expects to repurchase 46,000,000 common shares for cancellation in a modifie","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL8GWhnb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","ROIV","ABUS","IE00B3QW5Z07.USD","BK4112","IE00BKPKM429.USD","BK4588","LU0314104364.USD","IE00BN0W2W23.USD","BCDF","SG9999014039.USD","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","BK4007","PTH","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","BK4139","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670889472","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Roivant Sciences (ROIV) and Johnson & Johnson (JNJ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2670889472","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670889472?lang=en_us&edition=fundamental","pubTime":"2026-09-27 01:00","pubTimestamp":1790442018,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roivant Sciences (ROIV) and Johnson & Johnson (JNJ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-roivant-sciences-roiv-and-johnson-johnson-jnj-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-roivant-sciences-roiv-and-johnson-johnson-jnj-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FHLC","RXL","LU1280957306.USD","LU0426417589.USD","BK4532","GDOC","LU1929549753.HKD","ROIV","PTH","VHT","LU0943347566.SGD","BK4588","IE00BSNM7G36.USD","LU1061106388.HKD","JNJ","BK4550","LU0053666078.USD","LU0058720904.USD","LU2430703095.HKD","LU2750360997.AUD","FTXH","PJP","TRUH","LU0124676726.USD","LU0289739343.SGD","BK4585","MEDX","HCSG","XBI","XLV","BK4581","LU0069063385.USD","LU0545562505.USD","LU0912757837.SGD","LU2403377893.USD","IHE","IYH","LU1674673428.USD","BK4007","BMED","LABU","LU2756315664.SGD","LU1430594728.SGD","JDOC","IE00BDGV0183.EUR","LU0738911758.USD","LU1629891620.HKD","LU0234572021.USD","IXJ","LU0234570918.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669438437","title":"Wainwright maintains confidence in Immunovant’s pipeline despite CLE setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2669438437","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669438437?lang=en_us&edition=fundamental","pubTime":"2026-09-24 01:20","pubTimestamp":1790184011,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Douglas Tsao notes that this morning, Roivant Sciences (ROIV) reported that IMVT-1402 missed the Week 12 Cutaneous Lupus Er...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/wainwright-maintains-confidence-in-immunovants-pipeline-despite-cle-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/wainwright-maintains-confidence-in-immunovants-pipeline-despite-cle-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ROIV","BK4007","PTH","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669486413","title":"Sector Update: Healthcare","url":"https://stock-news.laohu8.com/highlight/detail?id=2669486413","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669486413?lang=en_us&edition=fundamental","pubTime":"2026-09-23 21:00","pubTimestamp":1790168425,"startTime":"0","endTime":"0","summary":"Healthcare stocks were steady premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF  slightly declining and the iShares Biotechnology ETF  inactive.Roivant Sciences  said its Immunovant  subsidiary plans to stop development of IMVT-1402 in cutaneous lupus erythematosus after a proof-of-concept study failed to achieve statistical significance on the primary endpoint. Shares of Immunovant and Roivant were down 6.1% and 1%, respectively, pre-bell.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PTH","IBB","XBI","LU0128526141.USD","BK4137","HCSG","LABU","LU0029874061.USD","BK4588","ROIV","IMVT","XLV","BK4581","BK4585","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669372486","title":"Update: US Equity Futures Slightly Lower Pre-Bell as Traders Await Developments in US-Iran Talks","url":"https://stock-news.laohu8.com/highlight/detail?id=2669372486","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669372486?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:48","pubTimestamp":1790167737,"startTime":"0","endTime":"0","summary":"(Updates with economic data, recent oil price movements, world markets' overview, and corporate stock movements.)US equity futures were slightly lower pre-bell Wednesday as traders awaited development","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IONQ","ROIV","LU1670627923.USD","WQTM","BK4139","LU1670628061.USD","BHP","COAL","BK4566","BK4142","IONZ","CQTM","BK4170","BK4585","CART","IMVT","IONL","QTUP","LU0300736062.USD","IONC","BK4141","BK4588","BK4168","BK4591","SLX","LU0300736492.USD","BK4517","IOYY","LU0266013472.USD","LU1366192091.USD","IONX","CARX","WNDR","PTH","BK4113","BK4602","RCL","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669048537","title":"Roivant Sciences price target raised to $41 from $37.50 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2669048537","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669048537?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:15","pubTimestamp":1790165711,"startTime":"0","endTime":"0","summary":"BofA analyst Chi Fong raised the firm’s price target on Roivant Sciences (ROIV) to $41 from $37.50 and keeps a Neutral rating on the shares after h...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-41-from-37-50-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-raised-to-41-from-37-50-at-bofa-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PTH","ROIV","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669483473","title":"Immunovant Falls After Lupus Drug Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2669483473","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669483473?lang=en_us&edition=fundamental","pubTime":"2026-09-23 20:04","pubTimestamp":1790165052,"startTime":"0","endTime":"0","summary":"BUZZ-Immunovant falls after lupus drug setback** Shares of biotech firm ImmunovantIMVT.Ofall 4.5% to $35.6 premarket** Stock set to open at its lowest level in over three months, if losses hold** Co p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nL6N45F0L8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4007","PTH","ROIV","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669269100","title":"Roivant Says IMVT-1402 Cutaneous Lupus Study Misses Primary Endpoint, Halts Development in CLE","url":"https://stock-news.laohu8.com/highlight/detail?id=2669269100","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669269100?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:05","pubTimestamp":1790161507,"startTime":"0","endTime":"0","summary":"Roivant says IMVT-1402 cutaneous lupus study misses primary endpoint, halts development in CLERoivant reported topline results from a proof-of-concept study of IMVT-1402 in cutaneous lupus erythematos","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nNDL5xYLBJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BN0W2V16.EUR","BK4588","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014039.USD","BK4139","IE00BGHQF748.EUR","LU2095319765.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","IE00BQXX3D17.EUR","BK4585","BK4112","IE00BQXX3C00.GBP","BCDF","LU0314104364.USD","SG9999014021.USD","IE00BN0W2W23.USD","ROIV","SG9999014005.SGD","PTH","NDAQ","IE00BQXX3F31.USD","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669676100","title":"Roivant Sciences - Imvt-1402 Demonstrates Favorable Safety and Tolerability Profile","url":"https://stock-news.laohu8.com/highlight/detail?id=2669676100","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669676100?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JH70M:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PTH","BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669100988","title":"Roivant Announces Topline Results from Proof-of-Concept Study of Imvt-1402 in Cutaneous Lupus Erythematosus","url":"https://stock-news.laohu8.com/highlight/detail?id=2669100988","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669100988?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JH70M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4007","PTH","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669006461","title":"Roivant Sciences - All Other Clinical Development Timelines Remain on Track","url":"https://stock-news.laohu8.com/highlight/detail?id=2669006461","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669006461?lang=en_us&edition=fundamental","pubTime":"2026-09-23 19:00","pubTimestamp":1790161201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260923:nTUA6JH70M:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","ROIV","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668928863","title":"Roivant Sciences Holds Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2668928863","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668928863?lang=en_us&edition=fundamental","pubTime":"2026-09-18 19:15","pubTimestamp":1789730117,"startTime":"0","endTime":"0","summary":"Roivant Sciences holds annual shareholder meetingRoivant Sciences held its annual general meeting on Sept. 16, 2026.Shareholders backed the reappointment of Ernst & Young LLP as independent auditor fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260918:nNDL5J39Jd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PTH","ROIV","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://roivant.com;investor.roivant.com","stockEarnings":[{"period":"1week","weight":-0.0539},{"period":"1month","weight":-0.1526},{"period":"3month","weight":-0.0284},{"period":"6month","weight":0.124},{"period":"1year","weight":0.9597},{"period":"ytd","weight":0.5452}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.071559},{"month":2,"riseRate":0.333333,"avgChangeRate":0.052607},{"month":3,"riseRate":0,"avgChangeRate":-0.087601},{"month":4,"riseRate":0.833333,"avgChangeRate":0.021573},{"month":5,"riseRate":0.5,"avgChangeRate":0.035469},{"month":6,"riseRate":0.833333,"avgChangeRate":0.042574},{"month":7,"riseRate":0.666667,"avgChangeRate":0.026843},{"month":8,"riseRate":0.666667,"avgChangeRate":0.010529},{"month":9,"riseRate":0.5,"avgChangeRate":0.020205},{"month":10,"riseRate":0.5,"avgChangeRate":0.070692},{"month":11,"riseRate":0.8,"avgChangeRate":0.02515},{"month":12,"riseRate":0.8,"avgChangeRate":0.23185}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}